Volver al Panel










Moderna, Inc. (MRNA)
Valores intradiarios en tiempo real
Resumen del Mercado
From:
To:
MRNA Intraday
No data available
SímboloMRNA
Fecha de SalidaDec 7, 2018
CEOMr. Stéphane Bancel M.B.A.
Empleados a Tiempo Completo4.7k
SectorHealthcare
IndustriaBiotechnology
PaísUnited States
BolsaNasdaqGS
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Rendimiento
| Período | Rentabilidad % | Cambio de Valor |
|---|---|---|
| 1 Día | +1.18% | +2.53 US$ |
| 5 Días | +9.78% | +19.27 US$ |
| 1 Mes | +50.22% | +72.30 US$ |
| 6 Meses | +295.52% | +161.59 US$ |
Analizando el Mercado con IA
Evaluando los últimos 30 días de historial y métricas fundamentales de MRNA...
Estadísticas Clave
Cap. de Mercado
86.33B
Relación P/E
N/A
Rend. de Div.
0.00%
Máx. 52 Semanas
$227.46
Mín. 52 Semanas
$22.28
Consenso de Analistas
CONSENSOMantener
ALCISTA521.7%
NEUTRAL1460.9%
BAJISTA417.4%
Objetivos de Precios de Analistas a 52 Semanas
Objetivo Mín.
$45.00
$45.00
Objetivo Máx.
$200.00
$200.00
Actual$216.27
Objetivo Prom.$122.67
Recomendaciones de Analistas
Precio Objetivo:$122.67($45.00 - $200.00)
Pensamientos de la Comunidad
Comparta su análisis y sentimiento sobre MRNA
Únase a la comunidad para compartir su análisis
Últimas Noticias para MRNA
BioNTech mRNA cancer immunotherapy misses first objective in key study
BioPharma Dive•13 oct 2026, 16:24

MRNA Stock Gains Over $4B in a Week: Time to Buy, Hold or Sell?
Zacks•13 oct 2026, 15:01

Phanes Therapeutics to participate in Longwood Healthcare Leaders Boston CEO, November 2-3, 2026
PR Newswire•13 oct 2026, 13:02

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
Motley Fool•13 oct 2026, 12:37

Moderna to Report Third Quarter 2026 Financial Results on Friday, November 6, 2026
ACCESS Newswire•13 oct 2026, 11:00


Moderna Is Now Worth More Than 3X as Much as BioNTech. Which Biotech Stock Is the Smarter Pick?
Motley Fool•13 oct 2026, 09:04
Moderna Stock Soared 14% as NIH Plans COVID-Style Push for Cancer Vaccines
TIKR•13 oct 2026, 02:23

Where Could Moderna's Next Growth Come From?
Trefis•12 oct 2026, 21:01

Here's Why Moderna (MRNA) Fell More Than Broader Market
Zacks•12 oct 2026, 20:50